Earnings Feed
Start Free
C4 Therapeutics, Inc.·4

Feb 18, 5:05 PM ET

Mahaney Paige 4

Research Summary

AI-generated summary

Updated

C4 Therapeutics CSO Paige Mahaney Receives 240,000-Share RSU Award

What Happened

  • Paige Mahaney, Chief Scientific Officer of C4 Therapeutics (CCCC), was granted 240,000 restricted stock units (RSUs) on Feb 13, 2026 (award code A). Those RSUs were reported at $0.00 per share (typical for RSU grants). Separately, on Feb 14, 2026 the filing reports the acquisition/conversion of 7,050 shares (transaction code M) related to vesting/conversion of a previously disclosed RSU grant. To satisfy tax withholding obligations, 2,446 shares were withheld/disposed at $1.89 per share for a withholding value of $4,623; this withholding is not a market sale.

Key Details

  • Transaction dates and amounts:
    • 2026-02-13: Grant of 240,000 RSUs (code A) — $0.00 per share.
    • 2026-02-14: Conversion/acquisition of 7,050 shares (code M) — $0.00 per share (reflects vesting/settlement of an earlier RSU grant).
    • 2026-02-14: 2,446 shares withheld for tax obligations (code F) at $1.89 = $4,623 (not a sale).
  • Shares owned following the reported transactions: not specified in the filing.
  • Footnotes of note:
    • F1: The 240,000 RSUs vest per schedule — 120,000 vest in three equal annual installments starting Feb 13, 2027; the other 120,000 vest in full on Feb 13, 2029, subject to performance-based acceleration.
    • F2: The 7,050-share acquisition reflects vesting/settlement of a previously disclosed RSU grant (originally reported Feb 18, 2025).
    • F3: The 2,446-share disposition is withholding to cover taxes and does not represent a market sale by the insider.
  • Filing date: Form 4 filed Feb 18, 2026. The filing covers transactions dated Feb 13–14, 2026; the filing’s timeliness is as reported on the SEC submission.

Context

  • These transactions are mostly grant/vesting-related (RSUs), not open-market purchases or opportunistic sales. RSU grants and routine tax-withholding are common compensation events and do not, by themselves, signal a buying or selling decision by the insider.
  • For derivative entries: the M-code here denotes conversion/acquisition upon vesting of previously granted RSUs (no cash exercise price was reported).